Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Chardan Capital 

EyePoint Pharmaceuticals Inc. diskutieren

EyePoint Pharmaceuticals Inc.

WKN: A2QJRU / Symbol: EYPT / Name: EyePoint Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

13,23 €
0,61 %

Einschätzung Buy
Rendite (%) 162,38 %
Kursziel 23,21
Veränderung
Endet am 16.05.26

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Mizuho from $30.00 to $26.00. They now have an "outperform" rating on the stock.
Ratings data for EYPT provided by MarketBeat

Einschätzung Buy
Rendite (%) 131,16 %
Kursziel 19,55
Veränderung
Endet am 29.05.26

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat

Einschätzung Buy
Rendite (%) 76,27 %
Kursziel 24,24
Veränderung
Endet am 17.06.26

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat

Einschätzung Buy
Rendite (%) 63,88 %
Kursziel 19,88
Veränderung
Endet am 06.08.26

Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at HC Wainwright from $22.00 to $23.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat

Einschätzung Buy
Rendite (%) 64,33 %
Kursziel 23,15
Veränderung
Endet am 07.08.26

Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $27.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat

Einschätzung Buy
Rendite (%) 50,28 %
Kursziel 33,89
Veränderung
Endet am 06.11.26

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $39.00. They now have an "outperform" rating on the stock.
Ratings data for EYPT provided by MarketBeat